肌萎缩侧索硬化症的骨骼肌生物标志物:一项大规模多队列蛋白质组学研究
该研究在多个纵向自然史队列中,对ALS患者和健康对照的血浆与脑脊液进行约7000种蛋白质的SOMAmer检测,识别出与ALS疾病状态和进展相关的生物标志物候选物,并在独立队列中验证,提示肌肉是这些标志物的重要来源。
要点
- 血浆中329种蛋白质在ALS与对照间显著差异调节,25种相对丰度变化>40%。
- PDLIM3、TNNT2、MYL11血浆升高最显著,ANTXR2、ART3降低最显著。
- 脑脊液中NEFL、NEFH、CHIT1、CA3、MYL11、GPNMB升高最显著。
核心结论
- 识别出一系列新型生物标志物,可能作为治疗开发中的反应标志物,并有助于揭示疾病生物学。
研究设计与样本
- 在多个纵向自然史研究中收集ALS患者和健康对照的临床表型数据与生物流体样本。
- 对血浆和脑脊液进行基于SOMAmer的约7000种蛋白质相对定量测量,并对候选物进行免疫分析验证。
主要发现
- 329种血浆蛋白质在ALS与对照间显著差异调节(校正p值<0.05),其中25种相对丰度变化>40%。
- PDLIM3、TNNT2和MYL11的log倍数升高最大,ANTXR2和ART3的log倍数降低最大。
- 疾病进展中,一组相似的血浆蛋白质升高(如PDLIM3、TNNT2、MYL11)或降低(如ANTXR2、ART3、MSTN)。
- 脑脊液中log倍数升高最大的蛋白质包括NEFL、NEFH、CHIT1、CA3、MYL11和GPNMB。
- 这些结果在独立复制队列中得到确认,组织特异性特征富集提示肌肉是这些生物标志物的重要来源。
关键数值与推荐
- 血浆KCNIP3在使用利鲁唑者中升高约60%。
- 免疫分析对血浆TNNT2和脑脊液GPNMB提供了正交验证。
临床怎么用
- 这些生物标志物候选物有潜力作为治疗开发中的反应标志物,并可能帮助理解ALS疾病生物学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response. To this end, we undertook a large-scale proteomic study in well-phenotyped cohorts to identify biomarker candidates of ALS disease state and disease progression. METHODS: Clinical phenotypic data and biofluid samples, collected from patients with ALS and healthy controls through multiple longitudinal natural history studies, were used to identify biomarker candidates. Slow off-rate modified aptamer (SOMAmer)-based relatively quantitative measurement of ~7,000 proteins was performed in plasma and cerebrospinal fluid (CSF), with immunoassay validation of candidates of interest. RESULTS: We identified 329 plasma proteins significantly differentially regulated between ALS and controls (adjusted p-value <0.05), with 25 showing >40% relative abundance. PDLIM3, TNNT2, and MYL11 had the greatest log-fold elevation, whereas ANTXR2 and ART3 had the greatest log-fold reduction. A similar set of plasma proteins was found to increase (eg, PDLIM3, TNNT2, and MYL11) or decrease (eg, ANTXR2, ART3, and MSTN) with disease progression. CSF proteins with the greatest log-fold elevation included NEFL, NEFH, CHIT1, CA3, MYL11, and GPNMB. These results were confirmed in an independent replication cohort. Moreover, tissue-specific signature enrichment suggests a significant contribution of muscle as a source of these biomarkers. Plasma KCNIP3 was elevated by ~60% in those on riluzole. Immunoassays provided orthogonal validation of plasma TNNT2 and CSF GPNMB. INTERPRETATION: We identified an array of novel biomarkers with the potential to serve as response biomarkers to aid therapy development, as well as to shed light on the underlying biology of disease. ANN NEUROL 2026;99:393-407.
引用
- Dergai O, Wuu J, Koziczak-Holbro M, et al. Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large-Scale, Multi-Cohort Proteomic Study. Ann Neurol. 2025. PMID: 41020397. doi:10.1002/ana.78046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。